# Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

> PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38206830-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38206830-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38206830-lanreotide-v1.json
- Content SHA-256: `e8a103f42e326c42fee06a2b802d7a3918b9431ca18eef55e74bdfe9897daf0c`

## Claims and source pins

### Headline

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

### Summary

PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

### Paragraph 1

PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`](#source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a))

## Sources

<a id="source-pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a"></a>
- **Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. · retained source version 1:2026-04-30:current:9a3b7f34f72ae55a13b9d614daf28e593d472ad01713bf8234b958ee2d57ad5d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38206830/) (`pubmed-observation-pmid-38206830-2026-04-30-9a3b7f34f72a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38206830-lanreotide-v1.json SHA-256: e8a103f42e326c42fee06a2b802d7a3918b9431ca18eef55e74bdfe9897daf0c.